Dr. Karen Herrera-Ferrá, MD: Founder and President of the Mexican Association of Neuroethics, Mexico City, Mexico
Karen Herrera-Ferrá lives in Mexico City and founded the Mexican Association of Neuroethics on July 2015. She is currently finishing a PhD program on Bioethics.
She was a visiting scholar at the Pellegrino Center for Clinical Bioethics (PCCB) at Georgetown University and then stayed to complete a one-year Post-doctorate in Neuroethics. She has a MA on Clinical Psychology, a Certificate on Cognitive Behavioral Therapy and another one on History of Religions. She has a one-year fellowship on Psychosis and another on OCD. She also has studies on Psychiatry and has a MD.
On May 2016 she developed a national project to formally introduce and develop neuroethics in her country, the main foci of this project is to depict and include national leaders in mental health, interested in neuroethics, so to inform and divulge this discipline among scholars and society. She also works as a mental health clinician in a private hospital, teaches Ethics and Health to third-year medical students, lectures in different hospitals and Universities in Mexico and is an Affiliated Scholar of the Neuroethics Studies Program at the PCCB at Georgetown University.
Her interests and research focuses on two main topics: Recurrent violent behavior and globalization of neuroethics in Latin America. In the former, she proposes to classify recurrent violent behavior as a psychiatric classifier as well as approaching it with advanced integrative convergence sciences (AISC) within the bio-psycho-social model and analyzing neuroethico-legal-social and political issues and concerns. In the latter work in progress, she analyses neuroethico-legal-social and political issues and concerns of the clinical use of neuroscience and neurotechnology in Latin America, specifically Mexico, including cultural, ethnical, economical and political caveats.
Bryn S. Esplin joined the Department of Humanities in Medicine at Texas A&M University after completing a two-year Clinical Ethics Fellowship at the Cleveland Clinic in Cleveland, OH.
She graduated cum laude from the University of California, Berkeley, with a degree in Rhetoric before pursuing her law degree. During law school, she externed with both the Supreme Court of Nevada and the Lou Ruvo Center for Brain Health in Las Vegas, NV, where she developed her passion for neuro-psychiatric ethics under the supervision of Dr. Dylan Wint.
Professor Esplin’s teaching brings together law, medicine, and popular culture to help students critically examine the social, ethical, and political implications that underlie medical decision-making. She currently teaches Clinical Ethics to first-year medical students, as well as an elective for third-year medical students that analyzes the social and philosophical meaning of death—including death by neurological criteria, the historical preoccupation with premature burial, the political consequences of neuro-enhancement, and the coming (or arrival) of cyborg technology.
She is a frequent speaker at both national and international conferences in Bioethics and Humanities, and her scholarship has appeared in numerous peer-reviewed journals, including Psychosomatics, Harvard’s Health and Human Rights Journal, The Journal of Clinical Ethics, and the American Journal of Bioethics, Neuroscience.
Current research projects include the use of placebos in functional disorders, as well as contemporary issues in law and clinical psychiatry regarding fiduciary duty and confidentiality.
JOIN US FOR FOOD AND DRINK BY THE HARBOR (each person will be responsible for his/her bill)
Catch up with old friends and collaborators and make new ones along the way!
• Date: Friday, November 11, 2016
• Time: 7:30pm until 9:30pm
• Location: Sally’s Fish House and Bar. One Market Place, San Diego, CA 92101. Phone: 619 358 6740
• Sally’s is 0.7 mile (15-min walk) from the Westin Gaslamp (where the poster session will be held)
Please RSVP to Karen Rommelfanger (firstname.lastname@example.org) by Tuesday, November 1st at 5pm EST.
Sahar Zafar is currently a doctoral candidate, focusing on Health and Research Policy (ABD) at the University of Baltimore. She currently holds a Master of Science in Biotechnology, with a concentration in Biodefense, from Johns Hopkins University. She has over 10 years of experience regulating Federal and Department of Defense (DoD) human subjects research (HSR) policies and HSR operations. Ms. Zafar currently manages the Defense Advanced Research Projects Agency’s (DARPA) human subjects research protection program, by ensuring that all Federal and DoD policies and regulations are followed with the highest ethical standards. She regularly participates as a subject matter expert on Assistant Secretary of Defense Research and Engineering Directorate (ASD R&E) panels for Federal and Defense human subjects research policies at conferences and meetings.
Ms. Zafar is currently working on her dissertation titled “Ethical, Legal and Societal Implications of Neuroscience and Technology Research and its Impact on Public Policy.” The central research question to be addressed in this study is how neuroscience and technology (neuro S/T) research addresses significant societal barriers to its public distribution and use. To conduct this study she has selected two programs from DARPA, and the National Institutes of Health (NIH). The programs selected were based on their development of neuro S/T that can be translated into use by the general public in the future.
In the current phase of her research, she is in the process of interviewing, agency personnel who are administrators, policy makers and/or science/technology specialists at DARPA, and NIH. Interviews that are being conducted with agency personnel are being conducted to understand strategies for implementation of initiatives and allocation of funding. Along with, institutional participants at DARPA, and NIH, interviews are being conducted with scientists and researchers conducting the funded neuro S/T researchers . These interviews should assist in establishing ethical and legal dimensions in public policies associated with neuro S/T research.
At the conclusion of this research study, the proposed hypotheses will either be accepted or rejected. Potentially, the data collected from this study can assist in drafting of guidance documents, policies, and educational material, about neuro S/T. These documents can assist in educating the general public, specifically the key demographics directly affected by this research about the actual efforts that are going into development of these technologies and the work of the agencies and researchers to mitigate the ethical, legal and societal implications of neuro S/T.
Nada Gligorov holds a PhD in Philosophy from the Graduate Center of the City University of New York. She is an associate professor in the Bioethics Program of the Icahn School of Medicine at Mount Sinai. She is also faculty for the Clarkson University-Icahn School of Medicine Bioethics Masters Program. In 2014, Nada founded the Working Papers in Ethics and Moral Psychology speaker series–a working group where speakers are invited to present well-developed, as yet unpublished work. This series has hosted speakers from Columbia, NYU, Cornell, Rutgers, and CUNY.
The primary focus of Nada’s scholarly work is the examination of the interaction between commonsense and scientific theories. Most recently, she authored of a monograph titled Neuroethics and the Scientific Revision of Common Sense forthcoming in 2016 (Studies in Brain and Mind, Springer). In this book, Nada examines the particular relationship between developments in neuroscience and commonsense moral concepts. Common sense, she argues, has been misinterpreted as a static, either foundational or degenerative, basis of our morality. She argues instead that common sense is an ever-shifting repository of theories from many domains. Within this discussion, Nada focuses on the application of neuroscience to human beings, i.e., the ethics of neuroscience. She also covers issues within the purview of the neuroscience of ethics, and she addresses the infiltration of neuroscientific knowledge into everyday parlance and the consequent impact on our commonsense morality and psychology. In particular, in her book, Nada examines the evolving influence of neuroscience on such concepts as free will, privacy, personal identity, pain, and death.
*This post was originally published on The Neuroethics Blog.
by Georgina Campelia
Georgina Campelia is currently a Ph.D. Candidate in Philosophy at the Graduate Center, CUNY, working under the supervision of Virginia Held. Her dissertation, “Virtue’s Web: The Virtue of Empathic Attunement and the Need for a Relational Foundation,” develops an account of empathic attunement, defends its status as a virtue, and sketches a relational ontology of virtue that would better accommodate the relationality of this and other important virtues.
More broadly, Georgina’s research focuses on ethics and feminist theory, with particular interests in virtue ethics, care ethics, empathy, the interdependence of ethics and epistemology, and interrelational conceptions of persons. Georgina’s work extends this theoretical work to neuroethics and medical ethics, where much of her research concerns using virtue ethics and care ethics to guide patient care, establishing structures to enable and encourage empathy, and creating greater awareness of the relational constitution of patient identity and medical decisions.
Georgina is currently an affiliate instructor at the Montefiore Einstein Center for Bioethics, where she teaches in their Certificate and Masters Programs. She also serves on the Steering Committee at the New York Society for Women and Philosophy (NYSWIP) and is a co-organizer of SWIPshop (a workshop for feminist philosophy).
As the lack of empathy in the world has become particularly apparent and troubling in light of the resistance to offering asylum for Muslim refugees (see this recent article from The Guardian), perhaps it makes sense that the study of empathy is booming (Coplan, 2014; Decety, 2012; de Waal, 2009). Philosophers question and defend its moral worth (Bloom, 2014), psychologists and primatologists consider its nature and origin (Hoffman, 2000; Waal, 2012), and neuroscientists explore its metaphysical structure (Singer, 2009; Zaki & Ochsner, 2012). Empathy offers a distinctive ground for interdisciplinary work and, yet, little has been done to advance cross-field communication. While some popular work offers broadly incorporated perspectives (de Waal, 2009), and there are some anthologies that include multiple disciplines (Coplan & Goldie, 2014; Decety, 2012), there is room for more robustly integrated research.
|Image of a baby macaque imitating facial expressions courtesy of Wikimedia.|
Keerthi Shetty is a Hellman Fellow in Science and Technology Policy at the American Academy. She contributes to several projects in the Science, Engineering, and Technology program including the Public Face of Science, Human Performance Enhancement, the Alternative Energy Future, and New Models for U.S. Science and Technology Policy. The Human Performance Enhancement Project is a project aimed as exploring societal and ethical issues around invasive and noninvasive cognitive enhancement technologies. Keerthi joined the American Academy after completing her doctoral work in immunobiology at Yale University. Keerthi’s thesis research involved studying the recruitment of RAG1 and RAG2—two important proteins of the immune system that help create antibodies—to chromatinized DNA during V(D)J recombination. At Yale, she was the co-president of the Yale Science Diplomats, a science policy group. Leading this organization, Keerthi helped develop a science lecture series for local high schools and the general public, organized policy writing workshops and seminars, and contacted legislators about funding issues concerning biomedical research. She was also named an eIntern for the State Department’s Virtual Student Foreign Service program, where she assisted with global science and technology projects. Keerthi holds a Ph.D. in immunobiology from Yale University and an A.B. in molecular biology from Princeton University.
*This post was originally published on The Neuroethics Blog.
By Anna Wexler
Anna Wexler is a PhD candidate in the HASTS (History, Anthropology, Science, Technology and Society) at MIT and a 2015-2016 visiting scholar at the Center for Neuroscience and Society at the University of Pennsylvania. Her dissertation focuses on the ethical, legal and social implications of emerging neuroscience technology, with a particular focus on the home use of noninvasive brain stimulation.
Just when it seemed like the consumer neurotechnology market couldn’t get any stranger—after all, who would’ve expected that a sleek white triangle could be placed on the forehead for “calm” or “energy” vibes—two new products recently hit the market that further complicate the challenges of regulating this emerging market. Halo Sport is a brain stimulator marketed for athletic enhancement that utilizes technology similar to transcranial direct current stimulation (tDCS), while Nervana, which began taking pre-orders in March, is the first noninvasive vagus nerve stimulation (VNS) device to be sold directly to the public in the United States.
Halo Neuroscience, the manufacturer of Halo Sport, advertises that its product “accelerates gains in strength, explosiveness, and dexterity.” In many ways, Halo Sport overcomes obstacles that have plagued other direct-to-consumer brain stimulation products. Because Halo Sport only claims to stimulate the motor cortex—which, conveniently for the company, lies beneath the area of the head where a pair of headphones might sit—the product does not utilize stray wires or a futuristic headset, but instead takes the recognizable shape of headphones. The beneficial effect of a familiar design should not be underestimated: many potentially useful technology tools have failed in no small part due to their unusual “look.”
Excerpt from NEW Leaders Dr. Laura Cabrera post originally published on Michigan State University’s Bioethics in the News page.
The alluring possibility of deleting memories has been the topic of movies such as Men in Black, Total Recall, and Eternal Sunshine of the Spotless Mind, yet in real life the chances of ever achieving such fine-tuned memory erasure is not a realistic bet. But suppose if by taking a pill we could forget about fear and about those things that cause us to be anxious? A New York Times article addressed exactly that possibility with the recent coverage of a drug to “cure” fear—by dampening memory. One factor influencing and shaping memory processes is their emotional intensity. Extensive psychological research and personal experiences confirm that events that occur during heightened states of emotion, such as fear, anger and joy, are generally more memorable than less dramatic occurrences. That research explains why you might remember exactly what you were doing when you found out about 9/11, but not necessarily be able to recall what you had for supper two days ago. Some memories with an intense emotional component might leave individuals susceptible to develop phobias, or possibly even post-traumatic stress disorder (PTSD).
Read the rest of the piece here.
*Editor’s note: This post was originally published on The Neuroethics Blog.
By Jennifer Laura Lee
Jenn Laura Lee recently received her undergraduate in neuroscience from McGill University in Montreal, Canada, and hopes to pursue a PhD in neurobiology this fall. Her current interests include the advancement of women in STEM and the ethics of animal experimentation.
The Bell Let’s Talk initiative swept through Canada on January 27, hoping to end the stigma associated with mental illness, one text and one share at a time. Michael Landsberg shares his thoughts in a short video on the Facebook page. “The stigma exists because fundamentally there’s a feeling in this country still that depression is more of a weakness than a sickness,” he explains. “People use the word depression all the time to describe a bad time in their life, a down time. But that’s very different than the illness itself.” Perhaps such a bold statement merits closer examination.